Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Changes in Stress-related Biomarkers and Cognitive Functioning as Predictors of Treatment Outcomes in Patients with Co-occurring Mental Health and Substance Use Disorders
EF 2022-23
Résumé
People with concurrent disorders (PCD; or co-occuring mental and substance use disorders) have poorer health and treatment outcomes than any mental health group and research on their treatment outcomes is severely lacking. Cognitive functioning and stress have been shown to impact treatment outcomes across substance-using and mental health groups, but have not been studied in PCD as a single clinical group. Our ongoing Health Canada-funded study (ROAR-CANADA) is the largest study ever of PCD worldwide. With data collected before, during, and after treatment (e.g., on patient profiles, self-report and administrative data) ROAR-CANADA aims to elucidate the predictors of outcomes, including relapse, overdose, and rehospitalization. This proposal aims to enrich the current assessment with the inclusion of neurocognitive tests and measures of stress, including biomarkers of acute and general stress. A total of 120 patients from the Red Fish Health Centre in Coquitlam, BC, will undergo two experiment sessions at baseline (?1 month from treatment admission) and at 3-month follow-up to: (1) characterize stress and cognitive functioning at treatment admission, (2) assess changes in stress and cognition over the course of treatment, and (3) examine the relevance of these changes in relations to treatment outcomes. We anticipate: (1) stress reactivity will decrease between baseline to follow-up, (2) performance on cognitive tests will improve from baseline to follow-up, and (3) improved stress and stress reactivity, and cognitive functioning will predict better outcomes in treatment. The knowledge obtained through this study will contribute to a more comprehensive assessment of concurrent disorders, and the risk factors and prevention strategies for overdose and relapse.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486235
Name
Todesco Stefanie
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Changes in Stress-related Biomarkers and Cognitive Functioning as Predictors of Treatment Outcomes in Patients with Co-occurring Mental Health and Substance Use Disorders
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Addiction; Biomarkers; Cognitive Functioning; Concurrent Disorders; Decision-Making; Impulsivity; Stress; Treatment
Abstract
People with concurrent disorders (PCD; or co-occuring mental and substance use disorders) have poorer health and treatment outcomes than any mental health group and research on their treatment outcomes is severely lacking. Cognitive functioning and stress have been shown to impact treatment outcomes across substance-using and mental health groups, but have not been studied in PCD as a single clinical group. Our ongoing Health Canada-funded study (ROAR-CANADA) is the largest study ever of PCD worldwide. With data collected before, during, and after treatment (e.g., on patient profiles, self-report and administrative data) ROAR-CANADA aims to elucidate the predictors of outcomes, including relapse, overdose, and rehospitalization. This proposal aims to enrich the current assessment with the inclusion of neurocognitive tests and measures of stress, including biomarkers of acute and general stress. A total of 120 patients from the Red Fish Health Centre in Coquitlam, BC, will undergo two experiment sessions at baseline (?1 month from treatment admission) and at 3-month follow-up to: (1) characterize stress and cognitive functioning at treatment admission, (2) assess changes in stress and cognition over the course of treatment, and (3) examine the relevance of these changes in relations to treatment outcomes. We anticipate: (1) stress reactivity will decrease between baseline to follow-up, (2) performance on cognitive tests will improve from baseline to follow-up, and (3) improved stress and stress reactivity, and cognitive functioning will predict better outcomes in treatment. The knowledge obtained through this study will contribute to a more comprehensive assessment of concurrent disorders, and the risk factors and prevention strategies for overdose and relapse.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Todesco, Stefanie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~